A new case report referencing degarelix was published on May 29, 2026, in the journal Frontiers in Medicine. The publication is titled "Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report."
The article is indexed under PubMed ID 42292172. As a case report, it documents a single clinical instance rather than presenting trial data or population-level findings.
No specific outcomes, efficacy data, or safety findings related to degarelix were provided beyond the publication title and journal listing. The report's focus, based on its title, centers on bilateral renal metastasis occurring after a patient underwent radical prostatectomy for prostate cancer.
Degarelix remains an approved compound. This publication adds to the existing body of medical literature discussing prostate cancer treatment and disease progression scenarios documented in clinical case reports.
Readers interested in learning more about degarelix, including its approved uses and background, can consult the compound overview for additional context.